SCLC6'7. Chemotherapy quickly became, and remains today, the essential treatment modality for SCLC8'9.
However, there has been some resurgence in interest in surgery for SCLC1O12. In this article, we critically review the place of surgery in the treatment of SCLC, and attempt to provide a balanced perspective on this controversial area of lung cancer treatment. BACKGROUND SCLC is usually disseminated at the time of initial diagnosis. About two-thirds of patients have 'extensive' disease and one-third have 'limited' disease. These staging terms were introduced when radiotherapy was the mainstay of SCLC treatment, and they are still used8'9. Limited disease is defined as tumour confined to one hemithorax and its associated mediastinal and supraclavicular lymph nodes. In other words, a tumour is limited if it can be encompassed by a radiotherapy portal. Most patients with limited stage disease have nodal or distant metastases, including bone marrow involvement if this is exhaustively looked for. If they are staged precisely, as is standard practice for NSCLC, most limited SCLCs are TNM (tumour, nodes, metastases) stage lIla and IlIb.
Chemotherapy is the usual treatment for extensive stage SCLC, while combined chemoradiotherapy is given for limited stage disease. Patients treated for extensive stage SCLC with chemotherapy have a median survival of about 9 months; without treatment, median survival is less than 2 months. Patients treated for limited stage SCLC with chemotherapy and radiotherapy have a median survival of 15-18 months; without treatment, median survival is about 3 months6'8'9. These statistics show the biological aggressiveness of most SCLCs.
When discussing surgical therapy for SCLC, it is useful to consider four clinical circumstances in which surgery has been advocated: SCLC presenting as a solitary pulmonary nodule (surgery for diagnosis and initial treatment); 'limited stage' SCLC (planned multimodality treatment consisting of induction chemotherapy followed by surgery); salvage surgery for local failures or chemoradiotherapy; and mixed-histology lung cancer (SCLC and NSCLC).
SMALL-CELL LUNG CANCER WITH SOLITARY PULMONARY NODULE
Within the group of limited SCLC patients a small subset (some 5% of all SCLC) have TNM stage I disease (small primary tumour without lymph node involvement). These patients usually have peripheral tumours (solitary pulmonary nodules) on chest X-ray and they are often symptom-freeI3-15. Bronchoscopy tends to be non-diagnostic and the diagnosis commonly has to await thoracotomy and resection. The prognosis for this small subset of SCLC patients is considerably better than for other patients with limited stage disease, resembling that of early stage NSCLC16. Some investigators have hypothesized that SCLC presenting as a solitary pulmonary nodule has an inherently different biology and natural history than the more usual SCLC14'15. In occasional patients with peripheral SCLC, retrospective examination of old chest X-rays has shown slow tumour growth over 1 to 3 years15,17,18. Slow growth of this kind is not rare in NSCLC19, but it is definitely at variance with the usual biological behaviour of SCLC. The accuracy of pathological diagnosis always comes under question when an apparent SCLC presents as a solitary pulmonary nodule. Some of these tumours may in fact be atypical carcinoids or well differentiated neuroendocrine carcinomas20'21 tumours that are much less aggressive and have a better prognosis.
The very select group of SCLC patients who present with a solitary pulmonary nodule are usually treated with a combination of surgery and chemotherapy, and cure is expected in about 50% of pathological stage I patients16.
Department of Thoracic Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263-0001, USA Correspondence to: John Urschel MD Whether this favourable outcome is due to the surgical resection, the chemotherapy, or the natural history is hard to know. Randomized trials have not been conducted in this group of patients and it is difficult to imagine any being done in the future. This subset of SCLC patients is too small to study in a trial, and many patients are diagnosed after one of the treatments in question, namely surgery, has already been delivered. Justification for surgery in peripheral SCLC comes from retrospective studies, which suggest that surgery contributes to the good survival seen in this subset of SCLC patients]3'16'22-24. These observations suggest that surgery is at least partly responsible for the good results reported for surgery and postoperative chemotherapy in peripheral SCLC. In addition, local tumour recurrence is infrequent when peripheral SCLC is treated surgi-cally101 1 126,27. Survival and local tumour control are better for peripheral SCLC treated with surgery and chemotherapy than they are for the more common limited stage SCLC treated with chemoradiotherapy. However, there are no data whereby surgery and radiotherapy can be compared as the local treatment in peripheral SCLC28. Surgery is generally preferred for peripheral SCLC25'29'30. Some surgeons, albeit a minority, have questioned the need for chemotherapy after resection of peripheral SCLC23. However, many clinical series of surgery and chemotherapy have shown better survival than in historical groups of patients treated by surgery alone31 1 ,3136. This information, together with an understanding of the biology of SCLC and the low morbidity of modern SCLC chemotherapy, makes it reasonable to recommend chemotherapy in all patients. As far as the timing of chemotherapy is concerned, there is no apparent advantage in giving chemotherapy before surgery in peripheral SCLC12. Surgery often establishes or confirms a diagnosis of SCLC in these patients, so the logical strategy is to give chemotherapy after surgical resection25.
INDUCTION CHEMOTHERAPY FOLLOWED BY SURGERY FOR LIMITED STAGE SCLC
Chemoradiotherapy is the current standard treatment for limited stage SCLC37 39. Although initial response rates of 80% are seen with this treatment, the 2-year survival rate is 20% or less. Local failure at the primary lung tumour site, or regional failure within lymph nodes, is the initial form of treatment failure in about half the patients. In some, this local-regional recurrence is the only identifiable site of treatment failure. Even in clinically complete treatment responders, studies have confirmed the failure of chemoradiotherapy to eradicate microscopic local-regional disease40. Surgical resection seems to give better localregional tumour control than radiotherapy10 126,27, so we survival in selected patients who do not have distant organ metastases27'30 '36'4. Many pilot studies of surgery as part of a multimodality treatment of limited stage SCLC have been done4148. Most protocols have also included postoperative radiotherapy to optimize local-regional tumour control. The studies have shown that surgical resection in this setting can be done with acceptable perioperative mortality. Local-regional control is better than what would be expected from chemoradiotherapy alone, and survival is modestly better than that usually reported for chemoradiotherapy. However, patient selection is obviously a factor in these encouraging results49. Only randomized trials can show, whether surgery is truly beneficial in this setting. Unlike the situation of SCLC presenting as a solitary pulmonary nodule, where randomized trials are simply not feasible, limited stage SCLC treatment can be studied in a randomized fashion.
Since the original Medical Research Council's trial comparing surgery with radiotherapy for SCLC, there has been one randomized trial comparing trimodality therapy of chemotherapy, surgery, and radiotherapy to chemoradiotherapy for limited stage SCLC50. This Lung Cancer Study Group trial did not show any survival advantage for the surgical treatment arm. However, the issue has not been completely resolved and may still be worthy of further clinical investigation. The Lung Cancer Study Group trial had small numbers, a 10% protocol violation rate, and included patients with extensive mediastinal lymph node involvement. In addition, some surgical centres had little previous experience with the technical difficulties of surgical resection in the setting of induction chemotherapy. These issues raise the possibility that there could be a modest survival benefit for trimodality therapy in selected patients with limited stage SCLC but that the study did not have the power to detect it. At present, surgical resection should only be considered for patients with limited stage SCLC in the context of a clinical trial.
SALVAGE SURGERY FOR LOCAL TREATMENT FAILURES OF CHEMORADIOTHERAPY
As discussed above, local-regional recurrence after chemoradiotherapy for limited stage SCLC is common.
Patients with recurrent disease, or with persistence of tumour at the primary site, do not respond well to further chemotherapy or radiotherapy. Therefore 'salvage' surgery has been considered for a select group of patients who appear to have isolated local-regional disease5l152. Experience with salvage surgery is limited, but long-term survival had been very infrequent51. Therefore this approach is difficult to justify except in the very unusual circumstance 3 might reasonably speculate that surgery could improve where the residual or recurrent tumour is truly confined to the lung (without any detectable lymph node or other metastatic involvement).
MIXED HISTOLOGY LUNG CANCER (SCLC AND NSCLC)
Some 5-10% of SCLCs have associated NSCLC elements within the tumourl2'53. The NSCLC component does not respond as well to chemoradiotherapy as does the SCLC component. This possibility should be borne in mind when the primary tumour in limited stage SCLC does not respond as well as expected to treatment. In this circumstance, repeat bronchoscopy and biopsy may show residual NSCLC tumour elements. If the patient has otherwise responded to treatment, operative criteria for NSCLC should be applied to guide further surgical therapy. In practical terms, mediastinoscopy is required to rule out mediastinal lymph node metastases. Patients with disease confined to the lung and hilum can then undergo surgical resection for the residual NSCLC tumour elements. Survival in this subset of patients is similar to that in NSCLC of equivalent stage12.
CONCLUSIONS
Surgical resection combined with postoperative chemotherapy is appropriate treatment for the 5% of SCLC patients who present with a small peripheral tumour of uncertain histology. In this specific circumstance, surgery establishes or confirms a diagnosis of SCLC, gives good local tumour control, and is at least partly responsible for the favourable 50% 5-year survival seen in this small subset of patients. However, these isolated favourable experiences with surgical treatment of SCLC should not be extrapolated to the general population of SCLC patients.
Surgery as a planned component of multimodality therapy for limited stage SCLC has not been shown to be effective. Any survival benefit that it may have is undoubtedly small. This idea is still worthy of further randomized trials, but for the time being surgery should not be considered outside the context of a clinical trial.
Salvage surgery for local failures of chemoradiotherapy is seldom beneficial, and the concept should be viewed with caution. SCLC tumours with NSCLC elements occasionally occur. If the SCLC responds well to standard treatment, surgery may be considered for the residual NSCLC elements. However, regionally advanced disease must be excluded by thorough staging before surgical resection can be recommended.
